B-cell Lymphoma Recurrent

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

InnoCare
InnoCareChina - Beijing
1 program
1
OrelabrutinibPhase 1/2Small Molecule1 trial
Active Trials
NCT04304040Unknown43Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
InnoCareOrelabrutinib

Clinical Trials (1)

Total enrollment: 43 patients across 1 trials

NCT04304040InnoCareOrelabrutinib

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

Start: Jul 2020Est. completion: Dec 202543 patients
Phase 1/2Unknown

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space